↑ Rising
Business
🔮 holds
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals shares climbed following positive Phase 3 trial results for its lipid-lowering drug, while competitor Ionis saw a decline.